Page 1, 2, 3, 4, 5
34. Pimentel M. Gut microbes and irritable bowel syndrome [webcast]. GastroIntestinal Health Foundation. July 20, 2012. http://www.gihealthfoundation.org/coe/ibs/webcast/2012/july/MPimentel/?link=2012/july
/MPimentel&cme_proj_id=12&actionPage=topics/Gut_Microbes_and_IBS/request-for-credit.cfm?cme_proj_id=12. Accessed on October 27, 2012.
35. Bouhnik Y et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999 May;94(5):1327–1331.
36. Pyleris E et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012 May;57(5):1321–1329.
37. Carbonero F. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012 Nov 28;3:448.
38. Million M. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes (Lond). 2013 Nov;37(11):1460–1466.
39. Medani M. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis. 2011 Jul;17(7):1620–1625
40. Elsheikh W. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide. 2014 Sep 15;41:131–137.
41. Rodríguez LA. Ruigómez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. 1999 Feb 27;318(7183):565–566.
42. Ibid.
43. Beatty JK. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014 Apr 14;20(14):3976–3985.
44. Zanini B. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012 Jun;107(6):891–899.
45. Hanevik K. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009 Apr 21;9:27.
46. Pokkunuri V. Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome. J Neurogastroenterol Motil. 2012 Oct;18(4):434–442.
47. Pimentel M. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–442.
48. Pokkunuri. Op cit.
49. Sung J et al Effect of repeated Campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. Neurogastroenterol Motil. 2013 Jun;25(6):529–537.
50. Pimentel M et al. Autoimmunity links vinculin to the pathophysiology of functional bowel changes following Campylobacter jejuni infection in a rat model. Dig Dis Sci. Epub 2014 Nov.
51. Kim G. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012 Dec;57(12):3213–3218.
52. Dridi B. High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One. 2009 Sep 17;4(9):e7063.
53. Youn YH, Park JS, Jahng JH, et al. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci. 2011 Jul;56(7):2059–2066.
54. Gottschall E. Breaking the Vicious Cycle: Intestinal Health Through Diet. Baltimore, ON: Kirkton Press Ltd.; 1994.
55. Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun. 2011 Mar;25(3):386–394. Epub 2010 Nov 20.
56. Pimentel M. A New IBS Solution. Sherman Oaks, CA; Health Point Press; 2006.
57. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003 Jan;48(1):86–92.
58. Kunkel D et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011 Jun;56(6):1612–1618.
59. Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1089–G1095.
60. Chatterjee S et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007 Apr;102(4):837–841.
61. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003 Jan;48(1):86–92.
62. Kim KM, Erosive esophagitis may be related to small intestinal bacterial overgrowth. Scand J Gastroenterol. 2012 May;47(5):493–498.
63. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol. 2004 Feb;7(1):19–28.
64. Leung Ki EL. Small intestine bacterial overgrowth. Rev Med Suisse. 2010 Jan 27;6(233):186–188,190–191.
65. DiBaise JK. Nutritional consequences of small intestinal bacterial overgrowth. Prac Gastroenterol. 2008;69:15–28.
66. Prizont R. Glycoprotein degradation in the blind loop syndrome: identification of glycosidases in jejunal contents. J Clin Invest. 1981 Feb;67(2):336–344.
67. Lauritano EC, Valenza V, Sparano L, et al. Small intestinal bacterial overgrowth and intestinal permeability. Scand J Gastroenterol. 2010 Sep;45(9):1131–1132.
68. Resnick C. Nutritional protocol for the treatment of intestinal permeability defects and related conditions. Nat Med J. March 2010.
69. Lactulose solution USP label. Pharmaceutical Assoc. Inc. Greenville, SC 29605.
70. Pimentel M. Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology. 2013 Jun;144(7):e1–e5.
71. Eisenmann A et al. Implementation and interpretation of hydrogen breath tests. J Breath Res. 2008 Dec;2(4):046002.
72. Costa MB. Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test. Arq Gastroenterol. 2012 Dec;49(4):279–283.
73. Pimentel M. Lecture at the SIBO Symposium. Portland OR; 2014.
74. Ibid.
75. Attaluri A. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010 Jun;105(6):1407–1411.
76. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006 Feb;130(2 Suppl 1):S78–S90.
77. Quin Tron Instrument Company Inc.Quin Tron catalog and information. 2012:22.
78. Pimentel. New IBS Solution. 2006.
79. Gottschall. Breaking the Vicious Cycle. 1994.
80. Siebecker A. SIBO Specific Diet food guide. Available at http://www.siboinfo.com/uploads/5/4/8/4/5484269/sibo_specific_diet_food_guide_sept_2014.pdf.
81. Ong DK. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010 Aug;25(8):1366–1373.
82. Nieves R, Jackson RT. Specific carbohydrate diet in treatment of inflammatory bowel disease. Tenn Med. 2004 Sep;97(9):407.
83. Choung RS. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011 May;33(9):1059–1067.
84. Shepherd SJ. The role of FODMAPs in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2014 Nov;17(6):605–609.
85. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011 Oct;24(5):487–495.
86. Pimentel M, Constantino T. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004 Jan;49(1):73–77.
87. Ibid.
88. Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev. 2002 Oct;7(5):410–417.
89. Chedid V. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16–24.
90. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13–27.
91. Lombardo L, Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy. Clin Gastroenterol Hepatol. 2010 June; 8(6):504–508.
92. Pimentel M, Lembo A. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22–32.
93. Scarpellini E et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314–1320.
94. Muniyappa P et al. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):400–404.
95. Scarpignato C. Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13–27.
96. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008 Apr;20(2):186–194.
97. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008 Jan;53(1):169–174
98. Mencarelli A. Inhibition of NF-kB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol. 2011 Oct 1;668(1–2):317–324.
99. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010 Sep;44(8):547–550.
100. Furnari M, Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010 Oct;32(8):1000–1006.
101. Bang C. Biofilm formation of mucosa-associated methanoarchaeal strains. Front Microbiol. 2014 Jul 8;5:353.
102. Pimentel M, Morales W. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–442.
103. Pimentel M. An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: Part 2. Am J Gastroenterol. 2010 Jun;105(6):1227–1230.
104. Pimentel M, Morales W. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–442.
105. Ochoa-Cortes F. Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm Bowel Dis. 2014 Jul;20(7):1259–1287.
106. Braden B. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009 Jun;21(6):632–638, e25.
107. Rösch W. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002 Jun;40(6):401–408.
108. Raedsch R. Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia–a retrospective cohort study. Z Gastroenterol. 2007 Oct;45(10):1041–1048.
109. Leichtle K. Experience reports of the application of Iberogast in children. Research report. Steigerwald: Arzneimittelwerk; 1999.
110. Gundermann KJ, Vinson B, Hänicke S. Die funktionelle Dyspepsie bei Kindern – eine retrospektive Studie mit einem Phytopharmakon. Päd. 2004;10:1–6.
111. Ploesser J, Weinstock LB, Thomas E. Low dose naltrexone: side effects and efficacy in gastrointestinal disorders. Int J Pharm Compd. March 2010.
112. Pimentel M, Morales W. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–442.
113. Pimentel M, Morales W. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–442.
114. Manabe N, Rao AS, Wong BS, Camilleri M. Emerging pharmacologic therapies for irritable bowel syndrome. Curr Gastroenterol Rep. 2010 Oct;12(5):408–416.
115. Pimentel. New IBS Solution. 2006.
116. Lauritano EC. Small intestinal bacterial overgrowth and intestinal permeability. Scand J Gastroenterol. 2010 Sep;45(9):1131–1132.
Page 1, 2, 3, 4, 5
|
